ResMed (NYSE:RMD) Stock Unloaded Rep. Kelly Morrison

Representative Kelly Morrison (D-Minnesota) recently sold shares of ResMed Inc. NYSE: RMD. In a filing disclosed on May 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in ResMed stock on April 28th. The trade occurred in the Representative's "TRUST 1" account.

Representative Kelly Morrison also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Meta Platforms NASDAQ: META on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 4/11/2025.
• Purchased $15,001 - $50,000 in shares of Broadcom NASDAQ: AVGO on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/11/2025.
• Sold $15,001 - $50,000 in shares of Ashtead Group OTCMKTS: ASHTY on 4/10/2025.
• Sold $1,001 - $15,000 in shares of Ashtead Group OTCMKTS: ASHTY on 4/10/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/24/2025.
• Purchased $15,001 - $50,000 in shares of Meta Platforms NASDAQ: META on 3/24/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/21/2025.
• Sold $100,001 - $250,000 in shares of Target NYSE: TGT on 3/21/2025.

ResMed Price Performance

NYSE:RMD opened at $246.63 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. ResMed Inc. has a one year low of $179.42 and a one year high of $263.05. The company has a fifty day moving average price of $224.59 and a 200 day moving average price of $234.16. The stock has a market cap of $36.16 billion, a P/E ratio of 29.12, a PEG ratio of 1.53 and a beta of 0.78.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The business's revenue was up 7.9% compared to the same quarter last year. Analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Thursday, May 8th. This represents a $2.12 annualized dividend and a dividend yield of 0.86%. ResMed's payout ratio is 23.79%.

Hedge Funds Weigh In On ResMed

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in ResMed by 23,982.6% in the first quarter. GAMMA Investing LLC now owns 733,556 shares of the medical equipment provider's stock valued at $164,207,000 after buying an additional 730,510 shares in the last quarter. Invesco Ltd. boosted its position in ResMed by 32.2% in the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock valued at $531,706,000 after buying an additional 566,046 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd boosted its position in ResMed by 1,168.5% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 590,895 shares of the medical equipment provider's stock valued at $132,272,000 after buying an additional 544,311 shares in the last quarter. Norges Bank acquired a new position in ResMed in the fourth quarter valued at about $118,605,000. Finally, Captrust Financial Advisors boosted its position in ResMed by 813.4% in the fourth quarter. Captrust Financial Advisors now owns 443,340 shares of the medical equipment provider's stock valued at $101,387,000 after buying an additional 394,803 shares in the last quarter. 54.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on RMD shares. Piper Sandler reduced their target price on shares of ResMed from $260.00 to $248.00 and set a "neutral" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group started coverage on shares of ResMed in a research note on Thursday, January 16th. They issued a "buy" rating for the company. Citigroup upgraded shares of ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, Royal Bank of Canada increased their target price on shares of ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a research note on Thursday, April 24th. One analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, ResMed has an average rating of "Moderate Buy" and an average price target of $258.83.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $242.25, for a total value of $484,500.00. Following the transaction, the director now directly owns 71,218 shares in the company, valued at $17,252,560.50. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $243.23, for a total transaction of $1,948,029.07. Following the completion of the transaction, the chief executive officer now owns 455,503 shares in the company, valued at approximately $110,791,994.69. This trade represents a 1.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 48,949 shares of company stock worth $11,335,320 over the last ninety days. Corporate insiders own 0.71% of the company's stock.

About Representative Morrison

Kelly Morrison (Democratic Party) is a member of the U.S. House, representing Minnesota's 3rd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Morrison (Democratic Party) is running for re-election to the U.S. House to represent Minnesota's 3rd Congressional District. She declared candidacy for the 2026 election. Kelly Morrison was born in Minneapolis, Minnesota, and lives in Deephaven. Morrison earned a B.A. in history from Yale University and an M.D. from Case Western Reserve University. She completed her residency in obstetrics and gynecology at Northwestern University. Morrison's career experience includes working as a physician.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.